Suppr超能文献

锂相关性甲状腺毒症:14例报告及发病率的统计分析

Lithium associated thyrotoxicosis: a report of 14 cases, with statistical analysis of incidence.

作者信息

Barclay M L, Brownlie B E, Turner J G, Wells J E

机构信息

Department of Nuclear Medicine, Christchurch Hospital, New Zealand.

出版信息

Clin Endocrinol (Oxf). 1994 Jun;40(6):759-64. doi: 10.1111/j.1365-2265.1994.tb02509.x.

Abstract

OBJECTIVE

Lithium is known to cause goitre and hypothyroidism, and has been associated less commonly with hyperthyroidism. We report a series of 14 patients with lithium associated thyrotoxicosis (LiAT), and have used epidemiological data to assess the association between long-term lithium treatment and the development of thyrotoxicosis.

DESIGN

Information for this retrospective study was obtained from records of patients attending the thyroid clinic between 1973 and 1991. Statistical analysis of the association between long-term lithium treatment and incidence of thyrotoxicosis was made using local thyrotoxicosis incidence figures and lithium prescription data.

MEASUREMENTS

Investigations included 99mTc pertechnetate thyroid scans, and blood analyses to measure serum T4, serum T3, free T4 index, and thyroid microsomal and thyroglobulin antibody titres.

RESULTS

During the 18-year period there were 14 patients with LiAT. This number of cases of thyrotoxicosis occurring in patients on lithium was more than three times greater than that predicted from local thyrotoxicosis incidence rates (P < 0.05). Scintiscans were obtained for 13 patients: 8 had toxic diffuse goitre, 2 toxic multinodular goitre, 1 toxic uninodular goitre, and 2 had a lack of visualization consistent with 'painless thyroiditis'. Nine patients received a course of carbimazole and 6 of these remain in remission. Six patients have received 131I therapy. Eight patients have become hypothyroid at follow-up (5 post 131I, 1 following a course of carbimazole, and the 2 with 'painless thyroiditis').

CONCLUSIONS

Statistical analysis has shown that long-term lithium therapy is associated with an increased risk of thyrotoxicosis. LiAT is a heterogeneous condition with differing underlying thyroid pathologies and the mechanisms remain uncertain. The management of LiAT should initially be with antithyroid medication, and 131I therapy should be given only to patients who do not obtain long-term remission.

摘要

目的

已知锂可导致甲状腺肿和甲状腺功能减退,较少与甲状腺功能亢进相关。我们报告了一系列14例锂相关性甲状腺毒症(LiAT)患者,并利用流行病学数据评估长期锂治疗与甲状腺毒症发生之间的关联。

设计

这项回顾性研究的信息来自1973年至1991年在甲状腺诊所就诊患者的记录。利用当地甲状腺毒症发病率数据和锂处方数据,对长期锂治疗与甲状腺毒症发病率之间的关联进行了统计分析。

测量

检查包括99m锝高锝酸盐甲状腺扫描,以及血液分析以测量血清T4、血清T3、游离T4指数、甲状腺微粒体和甲状腺球蛋白抗体滴度。

结果

在18年期间,有14例LiAT患者。锂治疗患者中发生的甲状腺毒症病例数比根据当地甲状腺毒症发病率预测的病例数高出三倍多(P<0.05)。对13例患者进行了闪烁扫描:8例为毒性弥漫性甲状腺肿,2例为毒性多结节性甲状腺肿,1例为毒性单结节性甲状腺肿,2例显示无摄取,符合“无痛性甲状腺炎”。9例患者接受了卡比马唑疗程治疗,其中6例仍处于缓解期。6例患者接受了131I治疗。8例患者在随访中出现甲状腺功能减退(5例在131I治疗后,1例在接受卡比马唑疗程治疗后,2例患有“无痛性甲状腺炎”)。

结论

统计分析表明,长期锂治疗与甲状腺毒症风险增加有关。LiAT是一种异质性疾病,潜在的甲状腺病理不同,其机制仍不确定。LiAT的治疗应首先使用抗甲状腺药物,仅对未获得长期缓解的患者给予131I治疗。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验